Journals / Psychiatry and behavioral sciences (Online) / 2019 / Cilt: 9 - Sayı: 2

Mydriasis Associated with Atomoxetine Treatment in a Child with Attention-Deficit/Hyperactivity Disorder (ADHD) and Specific Learning Disorder (SLD)

Pages
50–52
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although mydriasis is a rare side effect, clinicians should be aware that atomoxetine may cause mydriasis and inform the patients about these potential side effects when prescribing.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Attention-deficit/hyperactivity disorder (ADHD) is a chronic condition marked by persistent inattention, hyperactivity, and sometimes impulsivity, which begins in childhood and often lasts into adulthood.
📊
Key Findings & Data:Here, we report a patient with ADHD and specific learning disorder (SLD) who had a mydriasis following atomoxetine treatment.
💡
Conclusion & Impact:Although mydriasis is a rare side effect, clinicians should be aware that atomoxetine may cause mydriasis and inform the patients about these potential side effects when prescribing.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Attention-deficit/hyperactivity disorder (ADHD) is a chronic condition marked by persistent inattention, hyperactivity, and sometimes impulsivity, which begins in childhood and often lasts into adulthood. Here, we report a patient with ADHD and specific learning disorder (SLD) who had a mydriasis following atomoxetine treatment. The temporal relationship between the time of atomoxetine administration and development of mydriasis in the absence of an identifiable medical condition or confounding medications and the fact that there was no occurrence after atomoxetine discontinuation suggests that atomoxetine was responsible for mydriasis. Although mydriasis is a rare side effect, clinicians should be aware that atomoxetine may cause mydriasis and inform the patients about these potential side effects when prescribing.

🔖

Cite This Article

YALVAC, C. T., ISIK, U., ERKAN, E. (2019). Mydriasis Associated with Atomoxetine Treatment in a Child with Attention-Deficit/Hyperactivity Disorder (ADHD) and Specific Learning Disorder (SLD). Psychiatry and behavioral sciences (Online), Cilt: 9 - Sayı: 2, 50–52. https://ajindex.com/articles/302842

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Ercan ES, Bilac O, Uysal Ozaslan T, Rohde LA. Is the prevalence of ADHD in Turkish elementary school children really high? Social Psychiatry and Psychiatric Epidemiology 2015;50(7):1145–52
  2. Bahali K, Ipek H, Yalcin O, Orum O. Atomoxetine-induced mydriasis in a child patient. Eur Child Adolesc Psychiatry 2014;23(12):1231–2
  3. Alhatem FJ, Decker DH. Atomoxetine-Induced Mydriasis. J Child Adolesc Psychopharmacol 2008;18(5):539–41
  4. Haefliger IO, Herz MJ. Transient Mydriasis under Atomoxetine Treatment: Case Report and Brief Overview of the Literature. Klin Monbl Augenheilkd 2018;235(4):469–70
  5. Diagnostic and Statistical Manual of Mental Disorders. 5th edition American Psychiatric Publishing Arlington, VA; 2013
  6. Kose S, Akin E, Cetin M. Letter to the editor: Adverse drug reactions and causality: The Turkish version of Naranjo adverse drug reactions probability scale. Psychiatry and Clinical Psychopharmacology 2017;27(2):205–6
  7. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239–45
  8. Kreuser S, Riley J, Kolbasa K, Keerl A, Yappa U, Khan A, et al. A novel method to analyze atomoxetine-induced mydriasis in Sprague Dawley rats. J AALAM 2006;45(4)
  9. Dadashova R, Silverstone P. Off-label use of atomoxetine in adults: is it safe? Ment Illn 2012;4(2):e19
  10. Lachkar Y, Bouassida W. Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol 2007;18(2):129–33.